TARA PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

TARA ▼ -16.54% at T+5d

NEUTRAL call ✗ call lost -16.54% · α vs SPY -15.38% · entry $5.20 → $4.34

Next anchor: T+20d tomorrow

Last close $4.04 (close Jun 8) · -22.31% from $5.20 entry

Entry anchored
May 12, 03:59 PM ET
via Databento tick

T+1d

+1.92%

call +1.92% · α +1.15%

$5.30

settled 27d ago

T+5d

-16.54%

call -16.54% · α -15.38%

$4.34

settled 21d ago

T+20d

—

call — · α —

—

tomorrow

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Protara Therapeutics reported Q1 2026 net loss of $0.31 per share, beating consensus estimates of $0.37 loss, with cash of $177.4M to fund operations into 2028. Pipeline progress includes planned BLA submission for TARA-002 in lymphatic malformations in 2H 2027 and multiple data presentations in May 2026.

Actionable Insight

Monitor upcoming data presentations at AUA (May 15) and ISSVA (May 20) for TARA-002 in NMIBC and LMs, as positive results could drive near-term upside. Additionally, THRIVE-3 interim results in 2H 2026 represent a key catalyst for IV Choline Chloride.

Key Facts

Q1 2026 net loss $17.8M ($0.31/share) vs consensus $0.37 loss per share
Cash, equivalents and marketable securities $177.4M as of March 31, 2026
Plan to submit BLA for TARA-002 in LMs in 2H 2027
Enrollment completion for BCG-Unresponsive cohort in ADVANCED-2 trial expected 2H 2026
Interim results for THRIVE-3 (IV Choline Chloride) expected 2H 2026
Research and development expenses increased to $13.6M from $9.1M in prior year period

Financial Impact

Net loss per share improved 16.2% versus consensus; cash burn rate increased with R&D expenses up 48% YoY

net losscash positionR&D expenses

Risk Factors

Clinical trial enrollment delays or negative data readouts
Cash burn rate may require future capital raises before BLA submission
Regulatory setbacks for TARA-002 BLA or THRIVE-3

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

93% bullish (14 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3293938

13 reports for TARA

T+1T+5T+20T+60

67% Hit rate 6 of 9 directional calls best @ T+5▲ +9.58%May 26, 2026

Filters

Reports for TARA — sortable, filterable
	Type				Now
May 26, 2026 15d ago	EFFECT BEARISH ★ 5/10	$4.80 $4.34	▲ +9.58%	▲ +10.80%	$4.04 (+15.83%)
May 16, 2026 24d ago	ANALYST-UPGRADE BULLISH ★ 3/10	$6.20 $5.60	▼ −9.68%	▼ −8.34%	$4.04 (−34.84%)
May 15, 2026 25d ago	Press Release BULLISH ★ 7/10	$5.10 $4.92	▼ −3.53%	▼ −4.49%	$4.04 (−20.78%)
May 13, 2026 27d ago	8-K NEUTRAL ★ 4/10	$5.20 $4.34	▼ −16.54%	▼ −15.38%	$4.04 (−22.31%)
May 13, 2026 27d ago	Press Release NEUTRAL ★ 4/10	$5.20 $4.34	▼ −16.54%	▼ −15.38%	$4.04 (−22.31%)
Apr 28, 2026 6w ago	DEFA14A NEUTRAL ★ 2/10	$5.17 $5.66	▲ +9.48%	▲ +6.37%	$4.04 (−21.86%)
Apr 16, 2026 7w ago	ANALYST-UPGRADE BULLISH ★ 8/10	$5.13 $5.26	▲ +2.53%	▲ +1.55%	$4.04 (−21.25%)
Apr 16, 2026 7w ago	ANALYST-UPGRADE BULLISH ★ 8/10	$5.13 $5.26	▲ +2.53%	▲ +1.55%	$4.04 (−21.25%)
Apr 16, 2026 7w ago	ANALYST-UPGRADE MIXED ★ 6/10	$5.13 $5.26	▲ +2.53%	▲ +1.55%	$4.04 (−21.25%)
Apr 16, 2026 7w ago	ANALYST-UPGRADE BULLISH ★ 9/10	$5.13 $5.26	▲ +2.53%	▲ +1.55%	$4.04 (−21.25%)

US Market Status

Market Closed — Opens in 8h 59m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access